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Background
Gastrointestinal stromal tumours (GIST) are rare malig-
nancies characterised by their association with KIT onco-
gene mutations. Until now, population-based reports of
the incidence or survival of kit-confirmed GIST have been
rare, and none have originated in México.
Materials and methods
We reviewed the files in the Instituto Nacional de Can-
cerología to identify malignant mesenchymal tumours of
the digestive tract between 1995 and 2005, and performed
c-kit testing in the tumour samples.
Results
Seventeen cases were found with 88% of GIST localised in
the stomach, 5.8% in small intestine, and 5.8% in esopha-
gus. Fifthy-eight percent were classified as high risk of an
aggressive behaviour and 42% as low or very low risk.
Only one patient received treatment with imatinib mesi-
late and three had radiotherapy. The relative 3-year sur-
vival rate was 29.4% for the entire cohort.
Conclusion
We report the first review of incidence in a referral cancer
center in México. The incidence rate is low and compara-
ble with that of cancer registries from Northern America
and Europe. Survival was favourable in our pre-imatinib
population although it was low in high-risk cases. Prog-
nostic discrimination of the cases with intermediate, low,
or very low risk is inadequate, and these categories should
be considered jointly in the future. Our results will help
researchers in establishing baseline values against which
they can compare in the future, the impact of imatinib
and other Kit tyrosine inhibitors on survival.
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